The reimbursement restrictions set on the number of administration cycles set for the acute myeloid leukemia treatment 'Xospata' is expected to be lifted soon.

According to Dailypharm’s coverage, Astellas Korea recently finalized drug pricing negotiations with the National Health Insurance Service to expand reimbursement coverage for its Xospata (gilteritinib), a treatment used for relapsed or refractory acute myeloid leukemia (AML) with an FLT3 mutation.

This will accordingly allow greater prescribing flexibility for Xospata.

Under the current reimbursement standards, the use of Xospata is reimbursed for up to 2 cycles as induction therapy for patients with FLT3-mutated